The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
The psychosis spectrum in Parkinson disease
Open accessAbstract
In 2007, the clinical and research profile of illusions, hallucinations, delusions and related symptoms in Parkinson disease (PD) was raised with the publication of a consensus definition of PD psychosis. Symptoms that were previously deemed benign and clinically insignificant were incorporated into a continuum of severity, leading to the rapid expansion of literature focusing on clinical aspects, mechanisms and treatment. Here, we review this literature and the evolving view of PD psychosis. Key topics include the prospective risk of dementia in individuals with PD psychosis, and the causal and modifying effects of PD medication. We discuss recent developments, including recognition of an increase in the prevalence of psychosis with disease duration, addition of new visual symptoms to the psychosis continuum, and identification of frontal executive, visual perceptual and memory dysfunction at different disease stages. In addition, we highlight novel risk factors - for example, autonomic dysfunction - that have emerged from prospective studies, structural MRI evidence of frontal, parietal, occipital and hippocampal involvement, and approval of pimavanserin for the treatment of PD psychosis. The accumulating evidence raises novel questions and directions for future research to explore the clinical management and biomarker potential of PD psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“people with PD can experience a wide range of psychological difficulties, including anxiety, depression, apathy, impulse control disorders, and more rarely psychosis (ffytche et al., 2017; Simpson, McMillan, & Reeve, 2013).”
From Psychological interventions for people with Parkinson's disease in the early 2020s: Where do we stand? (2021) · cites this paper as ffytche et al., 2017
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This is consistent with reports of PD-VH declining cognitively more rapidly2 and showing possible subclinical cognitive variations early on in their VH4.”
From Deviations in effective connectivity explain different hallucination subtypes in Parkinson's disease psychosis (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Although these can fluctuate over the course of the condition, they generally tend to increase over time (ffytche et al., 2017).”
From Psychological interventions for people with Parkinson's disease in the early 2020s: Where do we stand? (2021) · cites this paper as ffytche et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Impaired cardiovascular autonomic function in Parkinson's disease with visual hallucinations
Oka, H., Yoshioka, M., Onouchi, K., Morita, M., Mochio, S., Suzuki, M., Hirai, T., Urashima, M., & Inoue, K. (2007) · Movement Disorders · doi:10.1002/mds.21581 · Cited by 21
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Self-citationSeppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Self-citationHallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Fénelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,035
Cummings, J. L., Isaacson, S., Mills, R., Williams, H., Chi‐Burris, K., Corbett, A., Dhall, R., & Ballard, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62106-6 · Cited by 954
Self-citationGlucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
The Parkinson Study Group (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401003 · Cited by 618
Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe
Harding, A., Broe, G. A., & Halliday, G. M. (2002) · Brain · doi:10.1093/brain/awf033 · Cited by 609
Minoshima, S., Foster, N. L., Sima, A. A. F., Frey, K. A., Albin, R. L., & Kuhl, D. E. (2001) · Annals of Neurology · doi:10.1002/ana.1133 · Cited by 560
Cited by
Sorted by citations
Items 101–200 of 356
Atlas-guided parcellation: Individualized functionally-homogenous parcellation in cerebral cortex
Li, Y., Liu, A., Fu, X., McKeown, M. J., Wang, Z. J., & Chen, X. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106078 · Cited by 20
Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
Tampi, R. R., Tampi, D. J., Young, J. J., Balachandran, S., Hoq, R., & Manikkara, G. (2019) · World Journal of Psychiatry · doi:10.5498/wjp.v9.i3.47 · Cited by 20
Les symptômes non-moteurs de la maladie de Parkinson de la physiopathologie au diagnostic précoce
Aubignat, M., Tir, M., & Krystkowiak, P. C. (2020) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.06.019 · Cited by 26
Yang, C., Chang, J., Liang, X., Bao, X., & Wang, R. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00213 · Cited by 19
Epac: A Promising Therapeutic Target for Vascular Diseases: A Review
Pan, Y., Liu, J., Ren, J., Luo, Y., & Sun, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.929152 · Cited by 18
Bidirectional Mendelian randomization study of psychiatric disorders and Parkinson’s disease
Wu, Q., Liu, S., Huang, X., Liu, J., Wang, Y., Xiang, Y., Tang, X., Xu, Q., Yan, X., Tang, B., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1120615 · Cited by 20
Imaging the Nonmotor Symptoms in Parkinson's Disease
Yousaf, T., Wilson, H., & Politis, M. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.001 · Cited by 18
Self-citationdos Santos, A. B., Bezerra, M. A., Rocha, M. E., Barreto, G. E., & Kohlmeier, K. A. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02041-9 · Cited by 18
Visual hallucinations in Parkinson’s disease are associated with thinning of the inner retina
Visser, F., Apostolov, V., Vlaar, A. M. M., Twisk, J. W. R., Weinstein, H. C., & Berendse, H. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-77833-1 · Cited by 18
Treatment of Advanced Parkinson’s Disease
Gilbert, R., & Khemani, P. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988720988904 · Cited by 18
Nonmotor Effects of Conventional and Transdermal Dopaminergic Therapies in Parkinson's Disease.
Kim, R., & Jeon, B. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.008 · Cited by 16
Dauwan, M., Hoff, J. I., Vriens, E. M., Hillebrand, A., Stam, C. J., & Sommer, I. E. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101752 · Cited by 19
Neuroscience robotics for controlled induction and real-time assessment of hallucinations
Bernasconi, F., Blondiaux, E., Rognini, G., Dhanis, H., Jenni, L., Potheegadoo, J., Hara, M., & Blanke, O. (2022) · Nature Protocols · doi:10.1038/s41596-022-00737-z · Cited by 17
Presence phenomena in parkinsonian disorders: Phenomenology and neuropsychological correlates
Reckner, E., Lisa Cipolotti, A., & Foley, J. A. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5303 · Cited by 17
Montagnese, M., Vignando, M., Ffytche, D. H., & Mehta, M. A. (2021) · Cortex · doi:10.1016/j.cortex.2021.11.001 · Cited by 17
Self-citationLee, Y., Park, M., Jeong, S. H., Baik, K., Kang, S., Yoon, S. H., Na, H. K., Sohn, Y. H., & Lee, P. H. (2023) · Neurology · doi:10.1212/wnl.0000000000207623 · Cited by 16
Witt, K., Levin, J., van Eimeren, T., Hasan, A., Ebersbach, G., for the German Parkinson’s Guideline Group, Bähr, M., Becktepe, J. S., Berg, D., Brockmann, K., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12576-x · Cited by 16
Ocular fixations and presaccadic potentials to explain pareidolias in Parkinson’s disease
Revankar, G. S., Hattori, N., Kajiyama, Y., Nakano, T., Mihara, M., Mori, E., & Mochizuki, H. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa073 · Cited by 16
Structural and Functional Correlates of Hallucinations and Illusions in Parkinson’s Disease
Marquès, A., Taylor, N. L., Roquet, D., Beze, S., Chassain, C., Pereira, B., O’Callaghan, C., Lewis, S. J. G., & Durif, F. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212838 · Cited by 15
Wal, P., Dwivedi, J., Wal, A., Vig, H., & Singh, Y. (2022) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-022-00425-5 · Cited by 15
Multimodal visual system analysis as a biomarker of visual hallucinations in Parkinson’s disease
Díez‐Cirarda, M., Cabrera‐Zubizarreta, A., Murueta‐Goyena, A., Strafella, A. P., Pino, R. D., Acera, M., Lucas‐Jiménez, O., Ibarretxe‐Bilbao, N., Tijero, B., Gómez‐Esteban, J. C., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11427-x · Cited by 15
Takamatsu, Y., Fujita, M., Ho, G. J., Wada, R., Sugama, S., Takenouchi, T., Waragai, M., Masliah, E., & Hashimoto, M. (2018) · Parkinson s Disease · doi:10.1155/2018/5789424 · Cited by 15
Sawczak, C., Barnett, A. J., & Cohn, M. (2019) · Parkinson s Disease · doi:10.1155/2019/5351749 · Cited by 15
Limbic thalamus atrophy is associated with visual hallucinations in Lewy body disorders
Matar, E., Brooks, D., Lewis, S. J. G., & Halliday, G. M. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.01.001 · Cited by 15
Rajagopalan, K., Rashid, N., Kumar, S., & Doshi, D. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2152600 · Cited by 15
Pisani, S., Gunasekera, B., Lu, Y., Vignando, M., Ffytche, D. H., Aarsland, D., Chaudhuri, К. R., Ballard, C. G., Lee, J., Kim, Y. K., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105081 · Cited by 14
Self-citationPrestimulus Low-Alpha Frontal Networks Are Associated with Pareidolias in Parkinson's Disease
Revankar, G. S., Kajiyama, Y., Hattori, N., Shimokawa, T., Nakano, T., Mihara, M., Mori, E., & Mochizuki, H. (2021) · Brain Connectivity · doi:10.1089/brain.2020.0992 · Cited by 14
Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship?
Urso, D., Gnoni, V., Filardi, M., & Logroscino, G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.808724 · Cited by 14
Genes and Nonmotor Symptoms in Parkinson's Disease
Lim, E., & Tan, E. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.029 · Cited by 14
Tavitian, A., Cressatti, M., Song, W., Turk, A. Z., Galindez, C., Smart, A., Liberman, A., & Schipper, H. M. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7937 · Cited by 14
Kumfor, F., Liang, C. T., Hazelton, J. L., Leyton, C. E., Kaizik, C., Devenney, E. M., Connaughton, E., Langdon, R. A., Mioshi, E., Kwok, J. B., et al. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5692 · Cited by 15
Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics
Butala, A., Shepard, M. D., & Pontone, G. M. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00007-1 · Cited by 13
Parkinsonism in the psychiatric setting: an update on clinical differentiation and management
Powell, A., Gallur, L., Koopowitz, L. F., & Hayes, M. W. (2020) · BMJ Neurology Open · doi:10.1136/bmjno-2019-000034 · Cited by 13
Visual hallucinations in psychiatric, neurologic, and ophthalmologic disease
Coerver, K. A., & Subramanian, P. S. (2020) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000701 · Cited by 15
GABA and hallucinations in Parkinson disease
ONOFRJ, M. C., & GILBERT, G. J. (2018) · Neurology · doi:10.1212/wnl.0000000000005985 · Cited by 13
Cognitive Correlates of Visual and Minor Hallucinations in Parkinson’s Disease
Lenka, A., Hegde, S., Arumugham, S. S., Singh, P., Yadav, R., & Pal, P. K. (2021) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2021.507 · Cited by 12
Pimavanserin Treatment for Parkinson’s Disease Psychosis in Clinical Practice
Dashtipour, K., Gupta, F., Hauser, R. A., Karunapuzha, C. A., & Morgan, J. C. (2021) · Parkinson s Disease · doi:10.1155/2021/2603641 · Cited by 12
Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms
Zhang, S., & Ma, Y. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i9.1127 · Cited by 12
Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis
Longardner, K., Wright, B. A., Alakkas, A., You, H., Xu, R., Liu, L., & Nahab, F. B. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278262 · Cited by 12
Functional Brain Networks of Minor and Well‐Structured Major Hallucinations in Parkinson's Disease
Baik, K., Kim, Y. J., Park, M., Chung, S. J., Sohn, Y. H., Jeong, Y., & Lee, P. H. (2023) · Movement Disorders · doi:10.1002/mds.29681 · Cited by 12
Udow, S. J., Freitas, M. E., Fox, S. H., & Lang, A. E. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.170361 · Cited by 12
Approach to the management of psychosis in Parkinson’s disease
Lenka, A., Gomathinayagam, V., & Bahroo, L. B. (2019) · Annals of Movement Disorders · doi:10.4103/aomd.aomd_27_19 · Cited by 12
Knolle, F., Garofalo, S., Viviani, R., Justicia, A., Ermakova, A. O., Blank, H., Williams, G. B., Arrondo, G., Ramachandra, P., Tudor-Sfetea, C., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102277 · Cited by 10
A Comprehensive Review of the Role of Biomarkers in Early Diagnosis of Parkinson’s Disease
Das, S., & Ramteke, H. B. (2024) · Cureus · doi:10.7759/cureus.54337 · Cited by 11
Spinosa, V., Brattico, E., Campo, F. F., & Logroscino, G. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103112 · Cited by 11
On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis
Pagán, F., Schulz, P. E., Torres-Yaghi, Y. A., & Pontone, G. M. (2024) · CNS Drugs · doi:10.1007/s40263-024-01084-1 · Cited by 11
Diplopia in Parkinson's disease: Indication of a cortical phenotype with cognitive dysfunction?
Naumann, W., Gogarten, J. H., Schönfeld, S., Klostermann, F., Marzinzik, F., & Schindlbeck, K. A. (2021) · Acta Neurologica Scandinavica · doi:10.1111/ane.13479 · Cited by 11
Deep Clinical Phenotyping of Parkinson’s Disease: Towards a New Era of Research and Clinical Care
Xu, Z., Shen, B., Tang, Y., Wu, J., & Wang, J. (2022) · Phenomics · doi:10.1007/s43657-022-00051-4 · Cited by 11
Management of Parkinson's disease psychosis—a European perspective
Pirker, W., Ferreira, J. J., Rascol, O., & Poewe, W. H. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101569 · Cited by 10
Bipolar spectrum disorders in neurologic disorders
Digiovanni, A., Ajdinaj, P., Russo, M., Sensi, S. L., ONOFRJ, M. C., & Thomas, A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1046471 · Cited by 10
Psychiatric and cognitive symptoms of Parkinson's disease: A life's tale
Amstutz, D., Sousa, M., Maradan‐Gachet, M. E., Debove, I., Lhommée, E., & Krack, P. (2024) · Revue Neurologique · doi:10.1016/j.neurol.2024.11.004 · Cited by 11
Jeyabalan, J. B., Vignesh Pandi, A., Sankar, V., Sivasamy, R., Dhanasekaran, M., & Justin, A. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08421-2 · Cited by 11
Sumi, Y., Ubara, A., Ozeki, Y., & Kadotani, H. (2021) · Acta Neurologica Scandinavica · doi:10.1111/ane.13555 · Cited by 10
Neurology versus Psychiatry? Hallucinations, Delusions, and Confabulations
Carota, A., & Bogousslavsky, J. (2019) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000494960 · Cited by 10
Karunakaran, K. B., Jain, S., Brahmachari, S. K., Balakrishnan, N., & Ganapathiraju, M. (2024) · Schizophrenia · doi:10.1038/s41537-024-00439-3 · Cited by 9
Nicastro, N., Stripeikyte, G., Assal, F., Garibotto, V., & Blanke, O. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102791 · Cited by 9
Creese, B., Albertyn, C. P., Dworkin, S., Thomas, R. S., Wan, Y.-M., & Ballard, C. G. (2018) · Journal of Neuropsychology · doi:10.1111/jnp.12169 · Cited by 9
Self-citationEmerging novel approaches to drug research and diagnosis of Parkinson’s disease
Zhen, X.-C., & Chu, H. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0369-7 · Cited by 9
Galet, B., Ingallinesi, M., Pegon, J., Thi, A. N. D., Ravassard, P., Biguet, N. F., & Meloni, R. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.190171 · Cited by 10
Othello syndrome in Parkinson’s disease: a systematic review and report of a case series
Michele, G. D., Palmieri, G. R., Pane, C., Iacovo, C. D. P. D., Perillo, S., Saccà, F., Michele, G. D., & Rosa, A. D. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05249-4 · Cited by 9
Non-visual hallucinations in Parkinson’s disease: a systematic review
Toh, W. L., Yolland, C. O. B., Gurvich, C., Barnes, J., & Rossell, S. L. (2023) · Journal of Neurology · doi:10.1007/s00415-022-11545-6 · Cited by 9
Chen, J., Chen, B., Zhao, D., Feng, X., Wang, Q., Li, Y., Chen, J., Bai, C., Guo, X., He, X., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14651 · Cited by 9
Changing the treatment paradigm for Parkinson’s disease psychosis with pimavanserin
Lyons, K. E., Pahwa, R., Hermanowicz, N. S., Davis, T. L., Pagán, F., & Isaacson, S. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1623669 · Cited by 8
Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease
Oikonomou, P., van Wamelen, D. J., Weintraub, D. A., Aarsland, D., Ffytche, D. H., Martínez‐Martín, P., Rodríguez‐Blázquez, C., Leta, V., Borley, C., Sportelli, C., et al. (2021) · Brain and Behavior · doi:10.1002/brb3.2086 · Cited by 8
Self-citationPsychosis in Parkinson's disease in a Southeast Asian cohort: prevalence and clinical correlates
Mok, V. W. L., Chan, L. G., Goh, J. C. B., & Tan, L. C. S. (2021) · Singapore Medical Journal · doi:10.11622/smedj.2021182 · Cited by 8
Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson’s Disease
Gibson, L. L., Pollak, T. A., Heslegrave, A., Hye, A., Batzu, L., Rota, S., Trivedi, D., Nicholson, T. R., Ffytche, D. H., Zetterberg, H., et al. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223182 · Cited by 8
Self-citationGu, R., Zhu, J., Zhong, M., Jiang, Y., Zhu, S., Wang, Y., Jiang, X., Shen, B., Yan, J., Zhang, L., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.929569 · Cited by 9
Wang, J., Lin, S., Bai, C., Zhang, H., Liu, H., Wang, M., & Guo, R. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf033 · Cited by 8
Cognitive and executive impairments in Parkinson’s disease psychosis: a Bayesian meta-analysis
Pisani, S., Gosse, L., Wieretilo, R., Ffytche, D. H., Velayudhan, L., & Bhattacharyya, S. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-331028 · Cited by 9
Self-citationMetabotropic glutamate receptors and nitric oxide in dopaminergic neurotoxicity
Bashkatova, V. G. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i10.830 · Cited by 7
Tuena, C., Riva, G., Murru, I., Campana, L., Goulene, K., Pedroli, E., & Stramba‐Badiale, M. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.992498 · Cited by 8
Rajagopalan, K., Rashid, N., & Doshi, D. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2220597 · Cited by 7
Robotically-induced hallucination triggers subtle changes in brain network transitions
Dhanis, H., Blondiaux, E., Bolton, T. A. W., Faivre, N., Rognini, G., Ville, D. V. D., & Blanke, O. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118862 · Cited by 8
A new tool to identify patients with Parkinson's disease at increased risk of dementia
Aarsland, D., Creese, B., & Chaudhuri, К. R. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30170-9 · Cited by 7
Self-citationVisual mismatch negativity in Parkinson's psychosis and potential for testing treatment mechanisms
Vignando, M., ffytche, D., Mazibuko, N., Palma, G., Montagnese, M., Dave, S., Nutt, D. J., Gabay, A. S., Tai, Y. F., Batzu, L., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae291 · Cited by 6
Self-citationPresence Hallucinations during Locomotion in Patients with Parkinson's Disease
Potheegadoo, J., Dhanis, H., Horvath, J. E., Burkhard, P. R., & Blanke, O. (2021) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13367 · Cited by 6
Phantom Boarder Relates to Experimentally‐Induced Presence Hallucinations in Parkinson's Disease
Blanke, O., Bernasconi, F., & Potheegadoo, J. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13684 · Cited by 6
Visual hallucinations in Parkinson's disease are associated with deficits in social perception
Albert, L., Vehar, N., Potheegadoo, J., Bernasconi, F., & Blanke, O. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251336196 · Cited by 5
Moriyama, T. S., Drukker, M., Gülöksüz, S., Have, M. T., de Graaf, R., van Dorsselaer, S., Günther, N., Bak, M., & van Os, J. (2020) · Psychological Medicine · doi:10.1017/s0033291720000793 · Cited by 6
Evaluating a novel behavioral paradigm for visual hallucinations in Dementia with Lewy bodies
Phillips, J. R., Matar, E., Martens, K. A. E., Moustafa, A. A., Halliday, G. M., & Lewis, S. J. G. (2021) · Aging Brain · doi:10.1016/j.nbas.2021.100011 · Cited by 6
Wang, Y., Li, D., Chen, Y., Zhu, S., Jiang, X., Jiang, Y., Gu, R., Shen, B., Zhu, J., Pan, Y., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1158188 · Cited by 6
Minor hallucinations in Parkinson’s disease with probable rapid eye movement sleep behavior disorder
Jiang, Y., Zhu, J., Zhao, Y., Li, D., Chen, Y., Wang, Y., Jiang, X., Shen, B., Pan, Y., Yan, J., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1205439 · Cited by 6
Pachi, I., Papadopoulos, V., Koros, C., Simitsi, A., Bougea, A. M., Bozi, M., Papagiannakis, N., Soldatos, R. F., Kolovou, D., Pantes, G. V., et al. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-230056 · Cited by 6
Psycho-sensory modalities of visual hallucinations and illusions in Parkinson's disease
Marquès, A., Beze, S., Lambert, C., Bonamy, L., de Chazeron, I., Rieu, I., Chiambaretta, F., & Durif, F. (2021) · Revue Neurologique · doi:10.1016/j.neurol.2021.04.007 · Cited by 6
Stampacchia, S., Bernasconi, F., Van De Ville, D., Amico, E., Pagonabarraga, J., Kulisevsky, J., & Blanke, O. (2025) · doi:10.1101/2025.04.17.649310 · Cited by 5
Clinical characteristics and treatment of psychosis in Parkinson’s disease: A narrative review
Stamenović, J., Živadinović, B., & Đurić, V. (2024) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001146 · Cited by 5
Real-time fMRI neurofeedback modulates induced hallucinations and underlying brain mechanisms
Dhanis, H., Gninenko, N., Morgenroth, E., Potheegadoo, J., Rognini, G., Faivre, N., Blanke, O., & Ville, D. V. D. (2024) · Communications Biology · doi:10.1038/s42003-024-06842-x · Cited by 5
D’Antonio, F., Teghil, A., Boccia, M., Gabrielli, G. B., Giulietti, G., Conti, D., Suppa, A., Fabbrini, A., Fiorelli, M., Caramia, F., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-65536-w · Cited by 5
Self-citationCBT for psychosis in Parkinson's disease: A framework for how and why
Foley, J. A., & Bell, V. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.04.023 · Cited by 5
Semantic dementia: a complex and culturally influenced presentation
Cole, R. H., Clark, C. N., & Poole, N. A. (2023) · BJPsych Bulletin · doi:10.1192/bjb.2022.100 · Cited by 5
Knolle, F., Arumugham, S. S., Barker, R. A., Chee, M. W. L., Justicia, A., Kamble, N. L., Lee, J., Liu, S., Lenka, A., Lewis, S. J. G., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00522-z · Cited by 5
Neuropsychological correlates of visual hallucinatory phenomena in Lewy body disease
Puntambekar, I., & Foley, J. A. (2023) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5950 · Cited by 5
Flanigan, J. L., Harrison, M. B., Patrie, J. T., Shah, B., Sperling, S. A., Wyman‐Chick, K. A., Dalrymple, W. A., & Barrett, M. J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1463426 · Cited by 5
Increasing Contrast Improves Object Perception in Parkinson's Disease with Visual Hallucinations
Díaz‐Santos, M., Monge, Z. A., Salazar, R. D., Gilmore, G. C., Neargarder, S. A., & Cronin‐Golomb, A. (2020) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13104 · Cited by 5
Kratter, I. H., Karp, J. F., Chang, Y., Whiteman, A. C., Feyder, M. T., Jorge, A., Richardson, R. M., & Henry, L. C. (2020) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20040077 · Cited by 5
Orayj, K. M. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s313212 · Cited by 5
Li, G., Zhu, J., Wu, X., Liu, T., Hu, P., Tian, Y., & Wang, K. (2022) · European Journal of Neurology · doi:10.1111/ene.15668 · Cited by 5
Jucevičiūtė, N., Balnytė, R., & Laucius, O. (2024) · Medicina · doi:10.3390/medicina60040606 · Cited by 5
Minor Visual Phenomena in Lewy Body Disease: A Systematic Review
Capogna, E., Pollarini, V., Quinzi, A., Guidi, L., Sambati, L., Criante, M. S., Mengoli, E., Venneri, A., Lodi, R., Tonon, C., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13051152 · Cited by 4
Hatsuta, H., Mizutani, M., Yagita, K., Sano, T., & Takao, M. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107935 · Cited by 4
Metadata
- Authors
- ffytche, D. H., Creese, B., Politis, M., Chaudhuri, K. R., Weintraub, D., Ballard, C., & Aarsland, D.
- Affiliations
- King's College London (GB)
- Corresponding author
- ffytche, Dominic H.
- Venue
- Nature Reviews Neurology
- Published
- 2017-01-20
- Volume
- 13
- Issue
- 2
- Pages
- 81-95
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC5656278
- OpenAlex
- W2579373654
- Cited by
- 355
- References
- 188
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 36 · 2023: 33 · 2022: 39 · 2021: 51 · 2020: 42 · 2019: 30 · 2018: 35 · 2017: 23
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Research Exeter (University of Exeter) (acceptedVersion)
- Figshare (submittedVersion)
- Funders
- National Institute for Health and Care Research (RP-PG-0610-10100)
- H. Lundbeck A/S
- National Institute of Neurological Disorders and Stroke (P50NS053488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- psychosis continuum, hallucinations, delusions, visual hallucinations, dementia risk, antiparkinsonian drugs, autonomic dysfunction, frontal executive dysfunction, memory impairment, pimavanserin, structural MRI, biomarkers, disease duration
- MeSH terms
- Humans, Parkinson Disease, Psychotic Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
